Study design
Patients aged ≥18y who had a first prescription claim for a target • medication during a four-month index period from April to July 2013 were identified (Fig 1) A six-month look-back period prior to the patient's first claim • (the 'index date') was used to categorize patients as treatmentnaïve (no claims for a target OAB medication or other drug in the antimuscarinic class) or treatment-experienced (≥1 prior OAB medication) during this time Prescription claims for a target drug were tracked for six months • after the index claim date to calculate time to end of persistence (defined by a maximum gap in therapy of 30 days or switching to another medication); time to end of persistence was censored for patients who remained on initial therapy through to Month 6
Patient distribution
The final cohort was 13,391 patients for the persistence and 
Treatment-naïve patients
There was significantly improved persistence with mirabegron vs • antimuscarinics (Table 3 and 
STUDY LIMITATIONS
This was an early analysis of private prescription claims, and it was • not possible to relate persistence to symptom severity
Patients classified • as treatment-naïve should be regarded as 'relatively' naïve, as they might have received medication before the 6-month look-back period Mirabegron was associated with higher levels of persistence • and adherence than antimuscarinics
The optimum place for mirabegron in the treatment algorithm • relative to antimuscarinics has not yet been established
Adherence was calculated by medication possession ratio (MPR) • through the 6-month period and was calculated using two methods:
MPR-fixed: the number of days supply, divided by 183 days in the follow-up period MPR-variable: the number of days supply, divided by the number of days between the first and last claims, plus the number of days supply of the last claim; patients required at least two prescriptions to qualify for the MPR-variable method.
Data for the following groups were captured: • -treatment status (experienced/naïve) -gender -age category (<46 years, 46-64 years, ≥65 years) -index product -number of co-existing medications (0, 1-3, 4-5, 6-8, >8) Only anonymized patient-level data were analysed; no ethical • committee review was required
Statistical analyses
Cox proportional hazards modeling was used to provide hazard • ratios (HR), 95% confidence intervals (CI), and p-values versus predefined reference covariates (shown in the Results tables)
Kaplan-Meier analysis was used to plot persistence rates over time •
In the MPR analysis, pairwise comparisons were calculated using • Mood's median statistical test 
